About Admin

This author has not yet filled in any details.
So far Admin has created 73 blog entries.

Biovica participates at SABCS, december 6-10, San Antonio

Biovica will attend the San Antonio Breast Cancer Symposium, an event that brings together oncology professionals from around the world. SABCS is the world’s leading breast cancer congress attracting more than 7,500 attendees from 90 countries. Read more at sabcs.org “At SABCS we will present new clinical study results in collaboration [...]

November 25th, 2016 13:30|News|

Biovica and Eisai inc. enter into lab services agreement

[Uppsala, Sweden, October 26, 2016]— Biovica and Eisai Inc. have entered into a lab services agreement to analyze DiviTum™, an assay measuring serum thymidine kinase, for improved drug evaluation in animal cancer models. In a preclinical setting at Eisai’s Andover innovative Medicine’s (AiM) Institute, Biovica’s non-invasive DiviTum™ technology will be used to test for evidence [...]

October 26th, 2016 08:30|Press Release|

Årsstämma Biovica International 2016

Biovica International höll årsstämma den 4:e oktober. VD Anders Rylander föredrog året i korthet och redogjorde för verksamhetsårets milstolpar. Biovica erhöll beslut om forskningsstöd från Horizon 2020 på 6,5 MSEK, med en första utbetalning på 2,2 MSEK. Biovica tog sin enskilt största order på 2,3 MSEK från en av världens ledande CRO:er, som förvärvat en [...]

October 11th, 2016 15:41|Press Release|

Meet Biovica at the World CDx Summit in Boston

Biovica will attend the 7th World Companion Diagnostic in Boston, October 18-21. The focus of the meeting is aligned with Biovicas strategy to rapidly progress exploratory biomarkers to registration, align clinical co-development and ensure reimbursement and market access success for precision therapies and assays. “At the World CDx meeting we look forward to meet partners [...]

September 28th, 2016 09:31|News|

Presentation of Biovica at unicorn summit capital market day

Anders Rylander, CEO and Mattias Bergqvist,VP Marketing & Clinical Development presented Biovica at an investors meeting at the IVA conference center in Stockholm. The meeting was arranged by Vator Securities. See below for the full presentation. (Swedish).

September 22nd, 2016 14:35|News|

Biovica attends capital market day

Biovica will give a company presentation at the annual Unicorn Summit Capital Market Day. The summit gathers some of the most interesting and innovative companies in Sweden and is arranged annually by Vator Securities AB. In addition to company presentations, the 150 attendees and participants have the opportunity to network with industry peers as well [...]

September 9th, 2016 09:00|News|

Kallelse till årsstämma i Biovica International AB

Styrelsen i Biovica International AB, org.nr 556774-6150, kallar härmed till årsstämma. Kallelsen i sin helhet kan läsas på länkad sida (länk) NOTICE OF ANNUAL GENERAL MEETING 2016 Biovica's shareholders are invited to the annual general meeting 2016. Shareholders meeting 2016 (link)

September 6th, 2016 11:17|News|

Expanded US patent approval for DiviTum™

Biovica has received expanded patent approval for the DiviTum™ kit-technology by the United States Patent and Trademark office. The patent protection for DiviTum™ now includes both the method and kit. DiviTum™ has patent protection in the US & Canada and across Europe, in total 49 countries. Biovica has developed DiviTum™, a non-invasive blood test, for [...]

August 31st, 2016 09:00|Press Release|

Biovica interviewed in Vatorpodden

Listen to Anders Rylander, CEO of Biovica and Mattias Bergqvist VP Sales & Marketing being interviewed in the latest edition of Vatorpodden. Anders and Mattias discuss challenges of cancer diagnostics and how Biovica assists with its products and technology. The interview is available in Swedish (only)

June 21st, 2016 13:36|News|

Biovica successfully raise sek 30 million in an oversubscribed issue of new shares

Biovica has successfully managed to ensure funds to deliver on the company’s business plan. Together with its financial advisor, Vator Securities, SEK 30 million have been raised in an oversubscribed issue of new shares. Biovica has developed a blood test for the rapid and reliable evaluation of therapy efficacy in patients with advanced cancer. The [...]

June 20th, 2016 11:45|Press Release|